GeneReach Biotechnology - Asset Resilience Ratio
GeneReach Biotechnology (4171) has an Asset Resilience Ratio of 28.49% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See working capital to net assets of GeneReach Biotechnology to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2018–2025)
This chart shows how GeneReach Biotechnology's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see balance sheet size of GeneReach Biotechnology.
Liquid Assets Composition Over Time
This chart breaks down GeneReach Biotechnology's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read total liabilities of GeneReach Biotechnology for a breakdown of total debt and financial obligations.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 0% |
| Short-term Investments | NT$244.49 Million | 28.49% |
| Total Liquid Assets | NT$244.49 Million | 28.49% |
Asset Resilience Insights
- Very High Liquidity: GeneReach Biotechnology maintains exceptional liquid asset reserves at 28.49% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
GeneReach Biotechnology Industry Peers by Asset Resilience Ratio
Compare GeneReach Biotechnology's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
CSL Ltd
AU:CSL |
Biotechnology | 0.41% |
|
Vaxcyte Inc
NASDAQ:PCVX |
Biotechnology | 41.54% |
|
Bachem Holding AG
SW:BANB |
Biotechnology | 0.00% |
|
Definium Therapeutics, Inc.
NASDAQ:DFTX |
Biotechnology | 38.51% |
|
Chongqing Zhifei Bio Products
SHE:300122 |
Biotechnology | -0.08% |
|
HLB Co. Ltd
KQ:028300 |
Biotechnology | 3.29% |
|
Sinopep-Allsino Biopharmaceutical Co. Ltd. A
SHG:688076 |
Biotechnology | 2.30% |
|
Zhejiang Ausun Pharmaceutical Co Ltd
SHG:603229 |
Biotechnology | 0.12% |
Annual Asset Resilience Ratio for GeneReach Biotechnology (2018–2025)
The table below shows the annual Asset Resilience Ratio data for GeneReach Biotechnology.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 28.34% | NT$249.69 Million ≈ $7.87 Million |
NT$881.05 Million ≈ $27.76 Million |
-8.56pp |
| 2024-12-31 | 36.90% | NT$393.49 Million ≈ $12.40 Million |
NT$1.07 Billion ≈ $33.60 Million |
+10.11pp |
| 2023-12-31 | 26.79% | NT$315.10 Million ≈ $9.93 Million |
NT$1.18 Billion ≈ $37.05 Million |
+25.84pp |
| 2022-12-31 | 0.95% | NT$15.36 Million ≈ $483.77K |
NT$1.62 Billion ≈ $51.10 Million |
+0.13pp |
| 2021-12-31 | 0.82% | NT$13.84 Million ≈ $436.04K |
NT$1.68 Billion ≈ $53.07 Million |
-2.62pp |
| 2020-12-31 | 3.44% | NT$42.72 Million ≈ $1.35 Million |
NT$1.24 Billion ≈ $39.08 Million |
-30.26pp |
| 2018-12-31 | 33.70% | NT$233.82 Million ≈ $7.37 Million |
NT$693.83 Million ≈ $21.86 Million |
-- |
About GeneReach Biotechnology
GeneReach Biotechnology Corp. develops, manufactures, and markets products for applied nucleic acid detection technology in Taiwan. The company offers various equipment, such as POCKIT Central Nucleic Acid Analyzer, POCKIT Micro Series, taco mini Automatic Nucleic Acid Extraction System, taco Prep Homogenization System, and cubee Mini-Centrifuge; reagents and consumables, including Human IVD Assa… Read more